RxDoctor Payments Data

Nathan Henry, APRN

Family · Mesquite, NVNPI 1063095982

Payments from drug & device makers

$1,678in general payments, 2019–2025

Across 73 payments — averaging $22.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$873
  • AstraZeneca$222
  • Biohaven Pharmaceutical Holding Company Ltd.$174
  • Johnson & Johnson$162
  • Lilly USA, LLC$150
  • Dexcom, Inc.$31
  • plus $66 from 4 others

What the payments were for

  • Food & beverage$1,678100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,678 in reported general payments places this provider in the 75th percentile of 1,501 family providers in Nevada.

See all family providers in Nevada

Medicare billing

Part B allowed, 2024
$120,904
Medicare patients
1,063
Services billed
2,062

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban14$19,990
EliquisApixaban15$19,106
RybelsusSemaglutide13$16,011
MounjaroTirzepatide11$11,018
Prednisone451$4,496
Cephalexin162$1,358
Rosuvastatin Calcium83$1,321
Atorvastatin Calcium121$1,083
Levothyroxine Sodium94$1,010
Ofloxacin28$1,001
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav110$847
Losartan Potassium81$841
Azithromycin227$840
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip28$795
Mupirocin98$764

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$162$19,99014 claims
Novo NordiskRybelsus$873$16,01113 claims
Lilly USA, LLCMounjaro$150$11,01811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,501 family providers in Nevada.

Other family in Mesquite

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →